Sirolimus
Research News and Information

Monday, November 23, 2009

Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment.

29 Nov 2009 The osteo-anabolic effects of intermittent parathyroid hormone (PTH) treatment require insulin-like growth factor (IGF) signaling through the IGF-I receptor. A major downstream target of the IGF-I receptor (via Akt) is the mammalian target of ... Read more...

Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant.

29 Nov 2009 The development of autoimmune blood cell cytopenias is a potentially life-threatening complication of solid organ transplantation, resulting from T-cell dysregulation from immunosuppressive medications. Conventional treatment with corticosteroids ... Read more...

Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.

29 Nov 2009 Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of the immune system caused by inadequate induction of apoptosis via the Fas pathway, mainly characterized by generalized lymphadenopathy, splenomegaly, and autoimmune cytopenias, ... Read more...

Latest indexed articles for 'Sirolimus'

These are the very latest articles for this heading:

• Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment. 29 Nov 2009
• Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. 29 Nov 2009
• Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome. 29 Nov 2009
• mTOR signaling in epileptogenesis: too much of a good thing? 5 Oct 2009
• Cell signaling. Aging is RSKy business. 30 Sep 2009
• Red blood cells carry out T cell growth and survival bioactivities that are sensitive to cyclosporine A. 29 Sep 2009
• Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. 29 Sep 2009
• Animal models of focal cortical dysplasia and tuberous sclerosis complex: recent progress toward clinical applications. 29 Sep 2009
• Focal brain malformations: seizures, signaling, sequencing. 29 Sep 2009
• Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. 29 Sep 2009
• DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. 22 Sep 2009
• Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. 20 Sep 2009
• Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2. 13 Sep 2009
• Gastric cancer: trastuzumab trial results spur search for other targets. 13 Sep 2009
• Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. 13 Sep 2009
• Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction. 13 Sep 2009
• Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. 12 Sep 2009
• The Vam6 GEF controls TORC1 by activating the EGO complex. 9 Sep 2009
• Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. 6 Sep 2009
• mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. 6 Sep 2009

See a longer list of these articles.

Technical information about 'Sirolimus'

Definition: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Registry Number: 53123-88-9

Descriptor UI: D020123

Alternative terms: Sirolimus; Rapamycin; I-2190A; I 2190A; I2190A; AY 22-989; AY 22 989; AY 22989; Rapamune; Wyeth Brand of Sirolimus;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antibiotics, Antineoplastic; Antifungal Agents; Immunosuppressive Agents; Anti-Bacterial Agents;

Tree Number: D02.540.505.760; D04.345.349.760;

History Note: 99; use SIROLIMUS (NM) 1980-97